Ironwood Pharmaceuticals Reports Positive Topline Data From Phase III Trial Of LINZESS (linaclotide) In Pediatric Patients Aged 6-17 With Functional Constipation; Study Met Primary And Secondary Endpoints
– Study met primary and secondary endpoints –
– Results add to body of data supporting the safety of linaclotide for this patient population –
– There are currently no FDA approved
